1887

Abstract

In a previous vaccination trial, inoculation of gene DNA failed to elicit a detectable antibody response, yet accelerated virus dissemination in most immunized cats following challenge with feline immunodeficiency virus. This result raised the possibility that cell-mediated immune responses had given rise to immune-mediated enhancement of infection. Since high-level replication of immunodeficiency viruses in lymphocytes requires cellular activation, antigen-specific responses or non-specific polyclonal activation may have increased the frequency of optimal target cells. In the present DNA vaccination trial, although designed so as to minimize non-specific polyclonal activation, immune-mediated enhancement was nonetheless observed in certain immunized cats. Moreover, rapid virus dissemination was associated with the presence of T-helper responses prior to challenge, and was linked to increased susceptibility of lymphocytes to infection. Immune activation may thus be a confounding factor in vaccination against lentivirus infection, diminishing vaccine efficacy and giving rise to immune-mediated enhancement.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-83-10-2515
2002-10-01
2020-08-09
Loading full text...

Full text loading...

/deliver/fulltext/jgv/83/10/0832515a.html?itemId=/content/journal/jgv/10.1099/0022-1317-83-10-2515&mimeType=html&fmt=ahah

References

  1. Aida Y., Pabst M. J.. 1990; Removal of endotoxin from protein solutions by phase separation using Triton X-114. Journal of Immunological Methods132:191–195
    [Google Scholar]
  2. Ascher M. S., Sheppard H. W.. 1990; AIDS as immune system activation. II. The panergic imnesia hypothesis. Journal of Acquired Immune Deficiency Syndromes3:177–191
    [Google Scholar]
  3. Bentwich Z., Maartens G., Torten D., Lal A. A., Lal R. B.. 2000; Concurrent infections and HIV pathogenesis. AIDS14:2071–2081
    [Google Scholar]
  4. Brichacek B., Swindells S., Janoff E. N., Pirruccello S., Stevenson M.. 1996; Increased plasma human immunodeficiency virus type 1 burden following antigenic challenge with pneumococcal vaccine. Journal of Infectious Diseases174:1191–1199
    [Google Scholar]
  5. Bukrinsky M. I., Stanwick T. L., Dempsey M. P., Stevenson M.. 1991; Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection. Science254:423–427
    [Google Scholar]
  6. Bush C. E., Donovan R. M., Markowitz N. P., Kvale P., Saravolatz L. D.. 1996; A study of HIV RNA viral load in AIDS patients with bacterial pneumonia. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology13:23–26
    [Google Scholar]
  7. Davey R. T. Jr, Chaitt D. G., Piscitelli S. C., Wells M., Kovacs J. A., Walker R. E., Falloon J., Polis M. A., Metcalf J. A., Masur H., Fyfe G., Lane H. C.. 1997; Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons. Journal of Infectious Diseases175:781–789
    [Google Scholar]
  8. Davis H. L., Michel M. L., Whalen R. G.. 1993; DNA-based immunization induces continuous secretion of hepatitis B surface antigen and high levels of circulating antibody. Human Molecular Genetics2:1847–1851
    [Google Scholar]
  9. Dawson J. D.. 1994; Comparing treatment groups on the basis of slopes, areas-under-the-curve, and other summary measures. Drug Information Journal28:723–732
    [Google Scholar]
  10. Eaton A. M., Ugen K. E., Weiner D. B., Wildes T., Levy J. A.. 1994; An anti-gp41 human monoclonal antibody that enhances HIV-1 infection in the absence of complement. AIDS Research and Human Retroviruses10:13–18
    [Google Scholar]
  11. Fust G., Toth F. D., Kiss J., Ujhelyi E., Nagy I., Banhegyi D.. 1994; Neutralizing and enhancing antibodies measured in complement-restored serum samples from HIV-1-infected individuals correlate with immunosuppression and disease. AIDS8:603–609
    [Google Scholar]
  12. Goletti D., Weissman D., Jackson R. W., Graham N. M., Vlahov D., Klein R. S., Munsiff S. S., Ortona L., Cauda R., Fauci A. S.. 1996; Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. Journal of Immunology157:1271–1278
    [Google Scholar]
  13. Hesselink W., Sondermeijer P., Pouwels H., Verblakt E., Dhore C.. 1999; Vaccination of cats against feline immunodeficiency virus (FIV): a matter of challenge. Veterinary Microbiology69:109–110
    [Google Scholar]
  14. Homsy J., Meyer M., Tateno M., Clarkson S., Levy J. A.. 1989; The Fc and not CD4 receptor mediates antibody enhancement of HIV infection in human cells. Science244:1357–1360
    [Google Scholar]
  15. Homsy J., Meyer M., Levy J. A.. 1990; Serum enhancement of human immunodeficiency virus (HIV) infection correlates with disease in HIV-infected individuals. Journal of Virology64:1437–1440
    [Google Scholar]
  16. Hosie M. J., Osborne R., Reid G., Neil J. C., Jarrett O.. 1992; Enhancement after feline immunodeficiency virus vaccination. Veterinary Immunology and Immunopathology35:191–197
    [Google Scholar]
  17. Huisman W., Karlas J. A., Siebelink K. H., Huisman R. C., de Ronde A., Francis M. J., Rimmelzwaan G. F., Osterhaus A. D.. 1998; Feline immunodeficiency virus subunit vaccines that induce virus neutralising antibodies but no protection against challenge infection. Vaccine16:181–187
    [Google Scholar]
  18. Johnston M. I.. 2000; The role of nonhuman primate models in AIDS vaccine development. Molecular Medicine Today6:267–270
    [Google Scholar]
  19. Jouault T., Chapuis F., Olivier R., Parravicini C., Bahraoui E., Gluckman J.-C.. 1989; HIV infection of monocytic cells: role of antibody-mediated virus binding to Fc-gamma receptors. AIDS3:125–133
    [Google Scholar]
  20. Karlas J. A., Siebelink K. H., van Peer M. A., Huisman W., Rimmelzwaan G. F., Osterhaus A. D.. 1998; Accelerated viraemia in cats vaccinated with fixed autologous FIV-infected cells. Veterinary Immunology and Immunopathology65:353–365
    [Google Scholar]
  21. Karlas J. A., Siebelink K. H. J., van Peer M. A., Huisman W., Cuisinier A. M., Rimmelzwaan G. F., Osterhaus A. D. M. E.. 1999; Vaccination with experimental feline immunodeficiency virus vaccines, based on autologous infected cells, elicits enhancement of homologous challenge infection. Journal of General Virology80:761–765
    [Google Scholar]
  22. Kostrikis L. G., Cao Y., Ngai H., Moore J. P., Ho D. D.. 1996; Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and I: lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent infectivity enhancement. Journal of Virology70:445–458
    [Google Scholar]
  23. Kovacs J. A., Baseler M., Dewar R. J., Vogel S., Davey R. T. Jr, Falloon J., Polis M. A., Walker R. E., Stevens R., Salzman N. P.. and others 1995; Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study. New England Journal of Medicine332:567–575
    [Google Scholar]
  24. Lallemant M., Baillou A., Lallemant-Le Coeur S., Nzingoula S., Mampaka M., M’Pelé P., Barin F., Essex M.. 1994; Maternal antibody response at delivery and perinatal transmission of human immunodeficiency virus type 1 in African women. Lancet343:1001–1005
    [Google Scholar]
  25. Lombardi S., Garzelli C., Pistello M., Massi C., Matteucci D., Baldinotti F., Cammarota G., Da Prato L., Bandecchi P., Tozzini F., Bendinelli M.. 1994; A neutralizing antibody-inducing peptide of the V3 domain of feline immunodeficiency virus envelope glycoprotein does not induce protective immunity. Journal of Virology68:8374–8379
    [Google Scholar]
  26. Montefiori D. C., Lefkowitz L. B. Jr, Keller R. E., Holmberg V., Sandstrom E., Phair J. P.. 1991; Absence of a clinical correlation for complement-mediated, infection-enhancing antibodies in plasma or sera from HIV-1-infected individuals. Multicenter AIDS Cohort Study Group. AIDS5513–517
    [Google Scholar]
  27. Montefiori D. C., Pantaleo G., Fink L. M., Zhou J. T., Zhou J. Y., Bilska M., Miralles G. D., Fauci A. S.. 1996; Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors. Journal of Infectious Diseases173:60–67
    [Google Scholar]
  28. Moraillon A., Barre-Sinoussi F., Parodi A., Moraillon R., Dauguet C.. 1992; In vitro properties and experimental pathogenic effect of three feline immunodeficiency viruses (FIV) isolated from cats with terminal disease. Veterinary Microbiology31:41–54
    [Google Scholar]
  29. O’Brien W. A., Grovit-Ferbas K., Namazi A., Ovcak-Derzic S., Wang H.-J., Park J., Yeramian C., Mao S.-H., Zack J. A.. 1995; Human immunodeficiency virus-type 1 replication can be increased in peripheral blood of seropositive patients after influenza vaccination. Blood86:1082–1089
    [Google Scholar]
  30. Ortigao-de-Sampaio M. B., Shattock R. J., Hayes P., Griffin G. E., Linhares-de-Carvalho M. I., Ponce de Leon A., Lewis D. J., Castello-Branco L. R.. 1998; Increase in plasma viral load after oral cholera immunization of HIV-infected subjects. AIDS12:F145–F150
    [Google Scholar]
  31. Ostrowski M. A., Krakauer D. C., Li Y., Justement S. J., Learn G., Ehler L. A., Stanley S. K., Nowak M., Fauci A. S.. 1998; Effect of immune activation on the dynamics of human immunodeficiency virus replication and on the distribution of viral quasispecies. Journal of Virology72:7772–7784
    [Google Scholar]
  32. Pancino G., Leste-Lasserre T., Burgard M., Costagliola D., Ivanoff S., Blanche S., Rouzioux C., Sonigo P.. 1998; Apparent enhancement of perinatal transmission of human immunodeficiency virus type 1 by high maternal anti-gp160 antibody titer. Journal of Infectious Diseases177:1737–1741
    [Google Scholar]
  33. Pedersen N. C., Ho E. W., Brown M. L., Yamamoto J. K.. 1987; Isolation of T-lymphotropic virus from domestic cats with an immunodeficiency-like syndrome. Science235:790–793
    [Google Scholar]
  34. Richardson J., Moraillon A., Baud S., Cuisinier A. M., Sonigo P., Pancino G.. 1997; Enhancement of feline immunodeficiency virus (FIV) infection after DNA vaccination with the FIV envelope. Journal of Virology71:9640–9649
    [Google Scholar]
  35. Richardson J., Moraillon A., Crespeau F., Baud S., Sonigo P., Pancino G.. 1998; Delayed infection after immunization with a peptide from the transmembrane glycoprotein of the feline immunodeficiency virus. Journal of Virology72:2406–2415
    [Google Scholar]
  36. Robinson W. E. Jr, Montefiori D. C., Mitchell W. M.. 1987; A human immunodeficiency virus type 1 (HIV-1) infection-enhancing factor in seropositive sera. Biochemical and Biophysical Research Communications149:693–699
    [Google Scholar]
  37. Robinson W. E. Jr, Kawamura T., Lake D., Masuho Y., Mitchell W. M., Hersh E. M.. 1990; Antibodies to the primary immunodominant domain of human immunodeficiency virus type 1 (HIV-1) glycoprotein gp41 enhance HIV-1 infection in vitro. Journal of Virology64:5301–5305
    [Google Scholar]
  38. Robinson W. E. Jr, Gorny M. K., Xu J. Y., Mitchell W. M., Zolla-Pazner S.. 1991; Two immunodominant domains of gp41 bind antibodies which enhance human immunodeficiency virus type 1 infection in vitro. Journal of Virology65:4169–4176
    [Google Scholar]
  39. Schutten M., Andeweg A. C., Bosch M. L., Osterhaus A. D. M. E.. 1995; Enhancement of infectivity of a non-syncytium inducing HIV-1 by sCD4 and by human antibodies that neutralize syncytium inducing HIV-1. Scandinavian Journal of Immunology41:18–22
    [Google Scholar]
  40. Schwartz D. H.. 1994; Potential pitfalls on the road to an effective HIV vaccine. Immunology Today15:54–57
    [Google Scholar]
  41. Siebelink K. H. J., Tijhaar E., Huisman R. C., Huisman W., de Ronde A., Darby I. H., Francis M. J., Rimmelzwaan G. F., Osterhaus A. D. M. E.. 1995; Enhancement of feline immunodeficiency virus infection after immunization with envelope glycoprotein subunit vaccines. Journal of Virology69:3704–3711
    [Google Scholar]
  42. Stanley S., Ostrowski M. A., Justement J. S., Gantt K., Hedayati S., Mannix M., Roche K., Schwartzentruber D. J., Fox C. H., Fauci A. S.. 1996; Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. New England Journal of Medicine334:1222–1230
    [Google Scholar]
  43. Staprans S. I., Hamilton B. L., Follansbee S. E., Elbeik T., Barbosa P., Grant R. M., Feinberg M. B.. 1995; Activation of virus replication after vaccination of HIV-1-infected individuals. Journal of Experimental Medicine182:1727–1737
    [Google Scholar]
  44. Sullivan N., Sun Y., Li J., Hofmann W., Sodroski J.. 1995; Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates. Journal of Virology69:4413–4422
    [Google Scholar]
  45. Sullivan N., Sun Y., Binley J., Lee J., Barbas C. F.III., Parren P. W. H. I., Burton D. R., Sodroski J.. 1998; Determinants of human immunodeficiency virus type 1 envelope glycoprotein activation by soluble CD4 and monoclonal antibodies. Journal of Virology72:6332–6338
    [Google Scholar]
  46. Takeda A., Tuazon C. U., Ennis F. A.. 1988; Antibody-enhanced infection by HIV-1 via Fc receptor-mediated entry. Science242:580–583
    [Google Scholar]
  47. Talbott R. L., Sparger E. E., Lovelace K. M., Fitch W. M., Pedersen N. C., Luciw P. A., Elder J. H.. 1989; Nucleotide sequence and genomic organization of feline immunodeficiency virus. Proceedings of the National Academy of Sciences, USA86:5743–5747
    [Google Scholar]
  48. Toth F. D., Szabo B., Ujhelyi E., Paloczi K., Horvath A., Fust G., Kiss J., Banhegyi D., Hollan S. R.. 1991; Neutralizing and complement-dependent enhancing antibodies in different stages of HIV infection. AIDS5:263–268
    [Google Scholar]
  49. Yamamoto J. K., Ackley C. D., Zochlinski H., Louie H., Pembroke E., Torten M., Hansen H., Munn R., Okuda T.. 1991; Development of IL-2-independent feline lymphoid cell lines chronically infected with feline immunodeficiency virus: importance for diagnostic reagents and vaccines. Intervirology32:361–375
    [Google Scholar]
  50. Zack J. A., Arrigo S. J., Weitsman S. R., Go A. S., Haislip A., Chen I. S. Y.. 1990; HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell61:213–222
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-83-10-2515
Loading
/content/journal/jgv/10.1099/0022-1317-83-10-2515
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error